Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013080 | 0.86 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL1013078 | 0.86 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL1968849 | 0.78 | HSD11B1 (0.49) | HTTHSD11B1LMNAALDH1A1HPGD | |
| SCHEMBL1013039 | 0.78 | HSD11B1 (0.63) | HTTHSD11B1 | |
| SCHEMBL30961274 | 0.77 | NR3C1 (0.49) | HTTLMNAALDH1A1HPGDKMT2A | |
| SCHEMBL1649728 | 0.76 | PABPC1 (0.50) | HTTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1018323 | 0.75 | NPC1 (0.50) | HTTLMNAALDH1A1HPGDKMT2A | |
| SCHEMBL9744263 | 0.74 | HSD11B1 (0.53) | HTTHSD11B1LMNAALDH1A1HPGD | |
| SCHEMBL5570021 | 0.73 | NFKB1 (0.54) | JUNNFKB1NFKB2RELA | |
| SCHEMBL4721408 | 0.72 | HTT (0.54) | HTTHSD11B1LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011049520-A1 | ADAMANTYL IMINOCARBONYL-SUBSTITUTED PYRIMIDINES AS INHIBITORS OF 1 1 BETAHSD1 | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | WO | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | HTT 1872/4885HSD11B1 2/4885LMNA 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.